Harri Visapää

812 total citations
30 papers, 634 citations indexed

About

Harri Visapää is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Radiation. According to data from OpenAlex, Harri Visapää has authored 30 papers receiving a total of 634 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Pulmonary and Respiratory Medicine, 12 papers in Molecular Biology and 8 papers in Radiation. Recurrent topics in Harri Visapää's work include Renal cell carcinoma treatment (11 papers), Prostate Cancer Diagnosis and Treatment (10 papers) and Renal and related cancers (8 papers). Harri Visapää is often cited by papers focused on Renal cell carcinoma treatment (11 papers), Prostate Cancer Diagnosis and Treatment (10 papers) and Renal and related cancers (8 papers). Harri Visapää collaborates with scholars based in Finland, United States and Sweden. Harri Visapää's co-authors include David B. Seligson, Aarno Palotie, Arie S. Belldegrun, Steve Horvath, Kauko Saarilahti, Mikko Tenhunen, Juhani Collan, Yunda Huang, Robert A. Figlin and Matthew Bui and has published in prestigious journals such as Cancer, The Journal of Urology and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Harri Visapää

30 papers receiving 624 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Harri Visapää Finland 12 389 300 146 130 112 30 634
Jianzhong Cao China 15 277 0.7× 232 0.8× 76 0.5× 76 0.6× 150 1.3× 58 620
Kazutoshi Murata Japan 15 264 0.7× 127 0.4× 113 0.8× 125 1.0× 63 0.6× 53 751
Rebecca Bütof Germany 14 321 0.8× 96 0.3× 157 1.1× 254 2.0× 80 0.7× 35 604
Zhen Zheng China 15 192 0.5× 292 1.0× 63 0.4× 40 0.3× 285 2.5× 41 682
Itai Pashtan United States 11 153 0.4× 166 0.6× 113 0.8× 87 0.7× 121 1.1× 25 504
Adnan Elhammali United States 10 201 0.5× 196 0.7× 48 0.3× 56 0.4× 118 1.1× 12 576
Ralf Kurek Germany 18 411 1.1× 178 0.6× 143 1.0× 73 0.6× 101 0.9× 29 756
Liru He China 18 263 0.7× 410 1.4× 33 0.2× 50 0.4× 197 1.8× 54 758
Jimmy Pramana Netherlands 5 145 0.4× 178 0.6× 50 0.3× 98 0.8× 171 1.5× 7 458
X. Zhang United States 10 183 0.5× 336 1.1× 124 0.8× 82 0.6× 85 0.8× 35 709

Countries citing papers authored by Harri Visapää

Since Specialization
Citations

This map shows the geographic impact of Harri Visapää's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Harri Visapää with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Harri Visapää more than expected).

Fields of papers citing papers by Harri Visapää

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Harri Visapää. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Harri Visapää. The network helps show where Harri Visapää may publish in the future.

Co-authorship network of co-authors of Harri Visapää

This figure shows the co-authorship network connecting the top 25 collaborators of Harri Visapää. A scholar is included among the top collaborators of Harri Visapää based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Harri Visapää. Harri Visapää is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pétas, Anssi, et al.. (2025). Long-term outcomes of LDR-brachytherapy for localized prostate cancer. Frontiers in Oncology. 14. 1326355–1326355. 1 indexed citations
2.
Seppälä, Tiina, et al.. (2023). Synthetic computed tomography based dose calculation in prostate cancer patients with hip prostheses for magnetic resonance imaging-only radiotherapy. Physics and Imaging in Radiation Oncology. 27. 100469–100469. 2 indexed citations
3.
Visapää, Harri, et al.. (2023). Salvage HDR brachytherapy for prostate cancer: a high-volume center experience on 100 consecutive patients. Scandinavian Journal of Urology. 57(1-6). 36–40. 5 indexed citations
4.
Järvinen, Petrus, Riikka Järvinen, Tuomas P. Kilpeläinen, et al.. (2019). Evolving Clinical Picture of Renal Cell Carcinoma: A Population-Based Study from Helsinki. Urologia Internationalis. 102(4). 390–398. 1 indexed citations
5.
Tenhunen, Mikko, Juha Korhonen, Mika Kapanen, et al.. (2018). MRI-only based radiation therapy of prostate cancer: workflow and early clinical experience. Acta Oncologica. 57(7). 902–907. 50 indexed citations
6.
Visapää, Harri. (2017). Switching from an LHRH Antagonist to an LHRH Agonist: A Case Report of 10 Finnish Patients with Advanced Prostate Cancer. Oncology and Therapy. 5(1). 119–123. 6 indexed citations
7.
Korhonen, Juuso T., Harri Visapää, Tiina Seppälä, et al.. (2016). Clinical Experiences of Treating Prostate Cancer Patients With Magnetic Resonance Imaging–Only Based Radiation Therapy Treatment Planning Workflow. International Journal of Radiation Oncology*Biology*Physics. 96(2). S225–S225. 3 indexed citations
8.
Nísen, Harry, et al.. (2014). Renal tumour anatomical characteristics and functional outcome after partial nephrectomy. Scandinavian Journal of Urology. 49(3). 193–199. 7 indexed citations
9.
Nísen, Harry, et al.. (2013). Renal tumour invasion index as a novel anatomical classification predicting urological complications after partial nephrectomy. Scandinavian Journal of Urology. 48(1). 41–51. 25 indexed citations
10.
Visapää, Harri, et al.. (2013). Papillary Renal Cell Cancer Is Strongly Associated with Simple Renal Cysts. Urologia Internationalis. 91(3). 269–272. 7 indexed citations
11.
Visapää, Harri, et al.. (2013). Gold seed fiducials in analysis of linear and rotational displacement of the prostate bed. Radiotherapy and Oncology. 110(2). 256–260. 10 indexed citations
12.
Collan, Juhani, et al.. (2011). Adaptive radiotherapy in muscle invasive urinary bladder cancer – An effective method to reduce the irradiated bowel volume. Radiotherapy and Oncology. 99(1). 61–66. 68 indexed citations
13.
Visapää, Harri, Kristina Hotakainen, Johan Lundin, Martti Ala‐Opas, & Ulf‐Håkan Stenman. (2010). The Proportion of Free PSA and Upgrading of Biopsy Gleason Score after Radical Prostatectomy. Urologia Internationalis. 84(4). 378–381. 14 indexed citations
14.
Visapää, Harri & Kimmo Taari. (2009). Combination of Paracetamol, Codeine and Lidocaine for Pain Relief during Transrectal Ultrasound Guided Biopsy of the Prostate. Scandinavian Journal of Surgery. 98(1). 55–57. 9 indexed citations
15.
Bui, Matthew, Harri Visapää, David B. Seligson, et al.. (2004). PROGNOSTIC VALUE OF CARBONIC ANHYDRASE IX AND KI67 AS PREDICTORS OF SURVIVAL FOR RENAL CLEAR CELL CARCINOMA. The Journal of Urology. 171(6 Part 1). 2461–2466. 146 indexed citations
16.
Visapää, Harri, Matthew Bui, Yunda Huang, et al.. (2003). Correlation of Ki-67 and gelsolin expression to clinical outcome in renal clear cell carcinoma. Urology. 61(4). 845–850. 89 indexed citations
17.
Visapää, Harri, David B. Seligson, Yunda Huang, et al.. (2003). Ki67, gelsolin and PTEN expression in sarcomatoid renal tumors. Urological Research. 30(6). 387–389. 10 indexed citations
18.
Visapää, Harri, David B. Seligson, Mervi Eeva, et al.. (2003). 8q24 Amplification in Transitional Cell Carcinoma of Bladder. Applied immunohistochemistry & molecular morphology. 11(1). 33–36. 9 indexed citations
19.
Visapää, Harri, David B. Seligson, Mervi Eeva, et al.. (2003). . Applied Immunohistochemistry. 11(1). 33–36. 1 indexed citations
20.
Rao, Jianyu, David B. Seligson, Harri Visapää, et al.. (2002). Tissue microarray analysis of cytoskeletal actin‐associated biomarkers gelsolin and E‐cadherin in urothelial carcinoma. Cancer. 95(6). 1247–1257. 76 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jianzhong Cao Breakdown of academic impact, for papers by Kazutoshi Murata Breakdown of academic impact, for papers by Rebecca Bütof Breakdown of academic impact, for papers by Zhen Zheng Breakdown of academic impact, for papers by Itai Pashtan Breakdown of academic impact, for papers by Adnan Elhammali Breakdown of academic impact, for papers by Ralf Kurek Breakdown of academic impact, for papers by Liru He Breakdown of academic impact, for papers by Jimmy Pramana Breakdown of academic impact, for papers by X. Zhang
Rankless by CCL
2026